Shandong Biopharmaceutical Research Institute

1. To confirm that the clinical efficacy of doripenem for injection is non-inferior to that of meropenem for injection 7±2 days after the last dose; 2. To evaluate the clinical efficacy within 24 hours after the last dose; 3. To evaluate the microbiological efficacy within 24 hours after the last dose; 4. To evaluate the comprehensive efficacy within 24 hours after the last dose; 5. To evaluate the long-term efficacy or clinical recurrence rate 14±2 days after the last dose; 6. To evaluate the safety of doripenem for injection in the treatment of complicated urinary tract infections.

On the basis of Phase II clinical trials, with target ulcer healing time as the primary indicator and placebo as the control, the effectiveness of the Aphrodisiac Oral Ulcer Patch in the treatment of recurrent aphthous ulcers (heart and spleen heat accumulation syndrome) was confirmed, and its safety and possible adverse reactions were further evaluated to provide a basis for the registration review of this product.

The purpose of this study is to conduct a human pharmacokinetic study on Febuxostat tablets (test preparation) provided by Beijing Yuekang Kaiyue Pharmaceutical Co., Ltd., to explore the pharmacokinetic changes of the test drug's absorption, distribution, and elimination in the human body, and to provide a reference for clinical application.